Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia

Brijesh Arora, Ruben A. Mesa, Ayalew Tefferi

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.

Original languageEnglish (US)
Pages (from-to)2373-2386
Number of pages14
JournalLeukemia and Lymphoma
Volume45
Issue number12
DOIs
Publication statusPublished - Dec 1 2004

    Fingerprint

Keywords

  • Agnogenic myeloid metaplasia
  • Angiogenesis
  • Anti-antigenesis treatment
  • MPD
  • Myelofibrosis
  • Myelofibrosis therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this